These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23889317)

  • 1. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO.
    W Collins P; Chalmers E; Hart D; Jennings I; Liesner R; Rangarajan S; Talks K; Williams M; R M Hay C;
    Br J Haematol; 2013 Sep; 162(6):758-73. PubMed ID: 23889317
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and quantification of factor VIII inhibitors.
    Verbruggen B
    Haemophilia; 2010 May; 16(102):20-4. PubMed ID: 19228204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor--two sides and the edge of a coin.
    Rangarajan S
    Haemophilia; 2011 Jan; 17(1):61-4. PubMed ID: 20518815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.
    James AH; Kouides PA; Abdul-Kadir R; Edlund M; Federici AB; Halimeh S; Kamphuisen PW; Konkle BA; Martínez-Perez O; McLintock C; Peyvandi F; Winikoff R
    Am J Obstet Gynecol; 2009 Jul; 201(1):12.e1-8. PubMed ID: 19481722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of patients having spontaneously occurring antibodies to antihaemophilic factor (factor VIII).
    Rizza CR; Edgcumbe JO; Pitney WR; Child JA
    Thromb Diath Haemorrh; 1972 Aug; 28(1):120-8. PubMed ID: 5074988
    [No Abstract]   [Full Text] [Related]  

  • 8. [Examination of the inhibitor to factor VIII in non-haemophilic patient].
    Suetomo M; Suehisa E; Nishimura K; Toyokawa M; Toku M; Fushimi R; Amino N; Miyai K; Izumi M; Ohtsuka A
    Rinsho Byori; 1991 Jul; 39(7):748-52. PubMed ID: 1920868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Directions for blood component therapy in blood coagulation disorders].
    Rasche H
    Klin Anasthesiol Intensivther; 1980; 21():136-51. PubMed ID: 6779052
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of inhibitors to factor VIII.
    Kasper CK
    Prog Hematol; 1981; 12():143-63. PubMed ID: 6803298
    [No Abstract]   [Full Text] [Related]  

  • 11. Laboratory issues in bleeding disorders.
    Lillicrap D; Nair SC; Srivastava A; Rodeghiero F; Pabinger I; Federici AB
    Haemophilia; 2006 Jul; 12 Suppl 3():68-75. PubMed ID: 16683999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: coagulopathy and factor inhibitors.
    Lal A; Brockstein B; Grinblatt D
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):925-7. PubMed ID: 19209143
    [No Abstract]   [Full Text] [Related]  

  • 13. A simple procedure for accurate quantitation of factor VIII inhibitors.
    Tse D; Fekete L; Shanbrom E
    Thromb Diath Haemorrh; 1970 Feb; 23(1):19-25. PubMed ID: 5420431
    [No Abstract]   [Full Text] [Related]  

  • 14. Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination.
    Luo YY; Zhang GS
    Haemophilia; 2011 May; 17(3):393-8. PubMed ID: 21323797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic and clinical aspects in patients with acquired circulating coagulation inhibitors].
    Gram J; Jespersen J; Pedersen JK
    Ugeskr Laeger; 1985 Apr; 147(16):1319-22. PubMed ID: 3923675
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of low-dose rituximab in a refractory acquired factor VIII inhibitor case secondary to pemphigus.
    Gao Y; Liu S; Ma G; Lv L; Su Y
    Acta Haematol; 2012; 127(1):20-2. PubMed ID: 21996575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
    Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
    Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic materials used in the treatment of coagulation defects.
    Smith JK; Bidwell E
    Clin Haematol; 1979 Feb; 8(1):183-206. PubMed ID: 367662
    [No Abstract]   [Full Text] [Related]  

  • 20. [Coagulopathy with autoantibodies to blood-clotting factors: overview and laboratory diagnosis].
    Arai M
    Rinsho Byori; 2004 Feb; 52(2):178-81. PubMed ID: 15027324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.